Skip to main content Help with accessibility Skip to main navigation

Ranibizumab

Indication

Choroidal neovascularisation (pathological myopia) NICE TA298
NICE TA298 - Ranibizumab for treating choroidal neovascularisation associated with pathological myopia 
Red

Brand:

Lucentis®

Nice TA:

298

Commissioning responsibility:

CCG

PbR excluded:

Yes

BNF chapter:
Eye

Background

1.1 Ranibizumab is recommended as an option for treating visual impairment due to choroidal neovascularisation secondary to pathological myopia only if the manufacturers of ranibizumab (branded or biosimilar) provide it at a discount level no lower than the discount agreed in the patient access scheme.

Recommendation

LSCMMG Recommendation:

Red

Reason for decision:

Specialist medicine

Supporting documents:

Decisions of Lancashire local decision making groups

Pending
Red
Red
Pending
Red
Red
Red
Red
What do the colours mean?

Last Updated: 01 - Dec - 2013